Home > Investors > Media

Media

9-Jun-2023	Creso Pharma and Apotheke Dr. Hysek partner to import MDMA and psilocybin treatments to Australia

5-Jun-2023	Creso Pharma trains sights on lucrative Australian market following change in licensing process

22-May-2023	Creso Pharma reports strong sales, licence extensions for Canadian subsidiary Mernova

19-May-2023	Creso Pharma raises A$2.5 million, streamlines balance sheet for growth strategy

17-May-2023	Creso Pharma strengthens market position on completing Health House International acquisition

15-May-2023	Creso Pharma hones in on pivotal Asian markets with Singapore and South Korea distribution deals

10-May-2023	Creso Pharma has eyes on multi-million dollar functional mushroom product market

8-May-2023	Creso Pharma gains Supreme Court green light for Health House acquisition

5-May-2023	Creso Pharma's subsidiary Halucenex demonstrates potential of psilocybin to treat PTSD

1-May-2023	Creso Pharma subsidiary secures new purchase orders and expands into Alberta

1-May-2023	Creso Pharma has strong foundation for growth across multiple verticals

6-Mar-2023	Creso Pharma boosts balance sheet through A$2.5 million convertible note issue

17-Feb-2023	Creso Pharma boosts finances for marketing push into US, psilocybin trial, with $2 million placement

9-Feb-2023	Creso Pharma has strong foundation for growth across multiple verticals in 2023

6-Feb-2023	Creso Pharma looks to bring psilocybin to Australian market after TGA downgrade

29-Jan-2023	Creso Pharma looks to acquire baby product company Abby and Finn; to streamline finance structure

23-Jan-2023	Creso Pharma expands Canadian footprint; secures largest purchase order ever

11-Jan-2023	Creso Pharma subsidiary Mernova to launch seven new products in Canada

9-Jan-2023	Creso Pharma draws additional A$500,000 on funding facility; shareholders approve A$2 million in placement participation by directors

7-Dec-2022	Creso Pharma subsidiary Halucenex doses first patient in Lucenex Phase 2 trial targeting PTSD

30-Nov-2022	Creso Pharma taps Peter Hatfull for board seat

23-Nov-2022	Creso Pharma starts to unlock Health House revenue streams and expansion initiatives

22-Nov-2022	Creso Pharma welcomes news it is “no longer the subject of investigation” by ASIC

21-Nov-2022	Creso Pharma inks scheme implementation deed to acquire Health House International

18-Nov-2022	Creso Pharma welcomes Canadian subsidiary’s large purchase orders from Saskatchewan cannabis co-operative

9-Nov-2022	Creso Pharma US subsidiary Sierra Sage Herbs expands Green Goo into Canada

3-Nov-2022	Creso Pharma’s Mernova awarded amended Health Canada sales licence

1-Nov-2022	Creso Pharma to raise $7.6 million through an issue of two separate convertible notes

19-Oct-2022	Creso Pharma to rebrand as Melodiol Global Health to better represent its international ambitions

13-Oct-2022	Creso Pharma US subsidiary Sierra Sage Herbs LLC inks wholesale agreement with accelerate360

10-Oct-2022	Creso Pharma accelerates growth strategy with director appointments, board transition and rebranding

6-Oct-2022	Creso Pharma to start psilocybin clinical trials into PTSD via wholly-owned Halucenex

4-Oct-2022	Creso Pharma subsidiary Mernova expands Canadian medicinal cannabis footprint

29-Sep-2022	Creso Pharma subsidiary Mernova Medicinal broadens Canadian footprint with provincial partnerships

14-Sep-2022	Creso Pharma psychedelics subsidiary Halucenex kicks off Phase 2 of psilocybin PTSD clinical trial

5-Sep-2022	Creso Pharma advances Health House International transaction

2-Sep-2022	Creso Pharma subsidiary secures US$214,000 purchase order from Walmart

29-Aug-2022	Creso Pharma launches into US CBD market on completing Sierra Sage Herbs acquisition

22-Aug-2022	Creso Pharma subsidiary Halucenex poised to begin psilocybin PTSD clinical trial following Health Canada update

15-Aug-2022	Creso Pharma subsidiary appoints renowned sports performance coach as brand ambassador ahead of product launch

8-Aug-2022	Creso Pharma’s Canadian subsidiary generates revenue of $3 million year-to-date

4-Aug-2022	Creso Pharma raising A$7 million for further US expansion

31-Jul-2022	Creso Pharma inks non-binding term sheet to acquire international pharmaceutical distributor Health House

25-Jul-2022	Creso Pharma target Sierra Sage Herbs secures private label manufacturing agreement with US online retailer

21-Jul-2022	Creso Pharma subsidiary Mernova delivers new Ontario cannabis sales

18-Jul-2022	Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

14-Jul-2022	Creso Pharma's Canadian subsidiary ImpACTIVE appoints three new brand ambassadors ahead of launch

12-Jul-2022	Creso Pharma secures LOI to commercialise anibidiol® products targeting pet health in South Korea

7-Jul-2022	Creso Pharma inks agreement to launch Sierra Sage Herbs pet care products in Singapore

30-Jun-2022	Creso Pharma agreement sees it spread wings in Taiwan’s growing animal health market

28-Jun-2022	Creso Pharma’s Canadian subsidiary Mernova lands first purchase order for Ritual Gold vaporiser products

14-Jun-2022	Creso Pharma subsidiary receives first order for new strains and takes third place in Cannabis Cup

30-May-2022	Creso Pharma’s psychedelics company signs psilocybin supply agreement

23-May-2022	Creso Pharma eyes potential pathway into Australian body care market through Dr Pickles agreement, shares higher

10-May-2022	Creso Pharma’s psychedelics subsidiary Halucenex secures psilocybe cubensis import permit from Health Canada

7-Apr-2022	Creso Pharma acquisition target expands US footprint

4-Apr-2022	Creso Pharma welcomes passing of Cannabis Act in US House of Representatives

31-Mar-2022	Creso Pharma secures LOI for commercialisation with Laboratorios Brouwer to broaden LATAM market sales

28-Mar-2022	Creso Pharma hits major mushroom milestones

20-Mar-2022	Creso Pharma subsidiary Mernova achieves market milestone and improves crop yield

16-Mar-2022	Creso Pharma set to unlock US product sales and manufacturing with Sierra Sage Herbs

28-Feb-2022	Creso Pharma’s psychedelics company cleared to start clinical trials

25-Feb-2022	Creso Pharma secures commitments to raise $5 million, plans to grow US footprint

21-Feb-2022	Creso Pharma set to launch new range of vaporisers as it expands its footprint in North America

15-Feb-2022	Creso Pharma’s acquisition of Sierra Sage Herbs see multiple product launches on the horizon

11-Feb-2022	Creso Pharma to develop hemp-based lozenge product and expand international opportunities

8-Feb-2022	Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

3-Feb-2022	Creso Pharma pushes into US CBD market with revenue-generating acquisition